Drug-Drug Interactions as a Challenge in the Monotherapy of Advanced or Metastatic Clear-Cell Renal Cell Carcinoma with VEGFR-Associated Tyrosine Kinase Inhibitors Arzneimittelinteraktionen als Herausforderung bei der Monotherapie des fortgeschrittenen oder metastasierten klarzelligen Nierenzellkarzinoms mit VEGFR-assoziierten Tyrosinkinase-Inhibitoren
Reinbold H, Goebell P, Merseburger AS (2026)
Publication Type: Journal article, Review article
Publication year: 2026
Journal
DOI: 10.1055/a-2775-6922
Abstract
Vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) play a central role in the treatment of advanced or metastatic clear-cell renal cell carcinoma (mRCC)- either in combination therapy or, in selected cases, as monotherapy. However, due to their mechanisms of action, these therapeutic agents may induce typical ad verse drug reactions (ADRs), commonly referred to as class effects. The use of multiple medications, particularly in old er patients with comorbidities, can further increase the risk of ADRs through potential drug-drug interactions. Managing VEGFR-TKI-relatedadverse effects in the contextof pa tient co-/multimorbidity and possible drug-drug interac tions represents a substantial challenge for both clinicians and patients. This article provides practical recommenda tions for side-effect and medication management, with a particular focus on pharmacokinetic and pharmacodynam ic drug-drug interactions. Tivozanib, a potent VEGFR-TKI, is well-suited and recommended as a first-line treatment op tion for mRCCduetoitscomparativelyfavorablesafetypro file and beneficial interaction potential.
Authors with CRIS profile
Involved external institutions
Germany (DE)How to cite
APA:
Reinbold, H., Goebell, P., & Merseburger, A.S. (2026). Drug-Drug Interactions as a Challenge in the Monotherapy of Advanced or Metastatic Clear-Cell Renal Cell Carcinoma with VEGFR-Associated Tyrosine Kinase Inhibitors Arzneimittelinteraktionen als Herausforderung bei der Monotherapie des fortgeschrittenen oder metastasierten klarzelligen Nierenzellkarzinoms mit VEGFR-assoziierten Tyrosinkinase-Inhibitoren. Aktuelle Urologie. https://doi.org/10.1055/a-2775-6922
MLA:
Reinbold, Hartmut, Peter Goebell, and Axel S. Merseburger. "Drug-Drug Interactions as a Challenge in the Monotherapy of Advanced or Metastatic Clear-Cell Renal Cell Carcinoma with VEGFR-Associated Tyrosine Kinase Inhibitors Arzneimittelinteraktionen als Herausforderung bei der Monotherapie des fortgeschrittenen oder metastasierten klarzelligen Nierenzellkarzinoms mit VEGFR-assoziierten Tyrosinkinase-Inhibitoren." Aktuelle Urologie (2026).
BibTeX: Download